WebFeb 17, 2024 · SAN DIEGO, Feb. 17, 2024 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced it will report financial results for the fourth quarter and full year 2024 and provide a corporate update at 4:30 p.m. ET on February 28, … WebFeb 6, 2024 · Otonomy has shifted development to OTO-313, an alternative formulation of gacyclidine that has improved properties compared to OTO-311. The company expects to initiate a Phase 1/2 clinical trial for OTO-313 in tinnitus patients in the first half of 2024.
Similar companies to Otonomy VentureRadar
WebUnited States, (619) 323-2200. www.otonomy.com. Profile. Investors (1) M&A Activity (1) M&A Connections (1) Analytics. Otonomy is an early stage drug development company focused on disorders which are treated by ENT (ear, nose, and throat) doctors, or otolaryngologists. WebMar 3, 2024 · OTONOMY. Otonomy, Inc. is a biopharmaceutical company. The Company is focused on the development of therapeutics for neurotology. The Company pipeline … ky lottery check your numbers
Otonomy Closes $38.5 Million Series B Financing - PR Newswire
WebApr 29, 2024 · YANGON—The Yangon regional government will sign a Memorandum of Understanding (MoU) with a consortium of Hong Kong and Taiwan companies next … WebOtonomy Inc Interest Coverage ratios, Interest expense growth, Ebitda growth starting from the third quarter 2024 to third quarter 2024, Trends and Ranking, Fundamental Ratios - CSIMarket Company Name, Ticker, Competitors, else.. WebApr 11, 2024 · 9.1. OTO 413: Otonomy. 10. Hearing Loss Pipeline Therapeutics Assessment. 11. Inactive Products in the Hearing Loss Pipeline. 12. Company-University Collaborations (Licensing/Partnering) Analysis. 13. proform pro 5000 treadmill warranty